Sign up for our daily briefing

Make your busy days simpler with Axios AM/PM. Catch up on what's new and why it matters in just 5 minutes.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on the day's biggest business stories

Subscribe to Axios Closer for insights into the day’s business news and trends and why they matter

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Stay on top of the latest market trends

Subscribe to Axios Markets for the latest market trends and economic insights. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sports news worthy of your time

Binge on the stats and stories that drive the sports world with Axios Sports. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Tech news worthy of your time

Get our smart take on technology from the Valley and D.C. with Axios Login. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Get the inside stories

Get an insider's guide to the new White House with Axios Sneak Peek. Sign up for free.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Catch up on coronavirus stories and special reports, curated by Mike Allen everyday

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Denver news?

Get a daily digest of the most important stories affecting your hometown with Axios Denver

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Des Moines news?

Get a daily digest of the most important stories affecting your hometown with Axios Des Moines

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Twin Cities news?

Get a daily digest of the most important stories affecting your hometown with Axios Twin Cities

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Tampa Bay news?

Get a daily digest of the most important stories affecting your hometown with Axios Tampa Bay

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Charlotte news?

Get a daily digest of the most important stories affecting your hometown with Axios Charlotte

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Nashville news?

Get a daily digest of the most important stories affecting your hometown with the Axios Nashville newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Columbus news?

Get a daily digest of the most important stories affecting your hometown with the Axios Columbus newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Want a daily digest of the top Dallas news?

Get a daily digest of the most important stories affecting your hometown with the Axios Dallas newsletter.

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Sign up for Axios NW Arkansas

Stay up-to-date on the most important and interesting stories affecting NW Arkansas, authored by local reporters

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Please enter a valid email.

Please enter a valid email.

Subscription failed
Thank you for subscribing!

Vuse brand e-cigarette flavor cartridges seen for sale in 2019. The FDA has cracked down on marketing of flavored products due to high rates of use among adolescents. Photo: Daniel Acker/Bloomberg via Getty Images

The Food and Drug Administration authorized three electronic cigarette products by Vuse Solo on Tuesday, citing benefits to adult smokers who are trying to quit tobacco.

Why it matters: It's the first such move by the agency in its effort to regulate new tobacco products. While e-cigarette manufacturers have touted the vape products as safer, the FDA has previously cracked down on them amid high rates of use among teens.

  • Products must be approved by the FDA to claim they help users quit smoking, according to an FDA press release.

Details: In the first greenlight since the FDA pushed e-cigarette makers to apply for approval, the agency approved Vuse Solo brand devices, which are distributed by R.J. Reynolds, a division of British American Tobacco.

  • Only tobacco-flavored pods were given the go-ahead.
  • The FDA also denied applications for 10 flavored Vuse Solo products.
  • Tuesday's action imposes tight marketing restrictions aimed at curbing "youth exposure to tobacco advertising," the FDA said in a statement announcing its decision.

Of note: The FDA said the authorized products' aerosols "are significantly less toxic than combusted cigarettes based on available data."

What they're saying: "Today's authorizations are an important step toward ensuring all new tobacco products undergo the FDA’s robust, scientific premarket evaluation," said Mitch Zeller, director of the FDA’s Center for Tobacco Products in a statement.

  • "The manufacturer's data demonstrates its tobacco-flavored products could benefit addicted adult smokers who switch to these products — either completely or with a significant reduction in cigarette consumption — by reducing their exposure to harmful chemicals," Zeller added.

Go deeper: FDA needs more time on Juul e-cigarette ban decision

See Axios' full coverage on vaping

Go deeper

Oct 14, 2021 - Health

FDA panel unanimously endorses Moderna boosters for certain populations

A pharmacist prepares to give a COVID-19 booster vaccination. Photo: Karwai Tang/Getty Images

Members of the Food and Drug Administration's vaccine expert panel on Thursday endorsed boosters for Moderna recipients who are at high risk of severe COVID-19, occupational exposure to COVID-19 or are 65 years and older.

Why it matters: The unanimous decision mirrors the FDA conditions for those who qualify for a Pfizer booster.

Updated 14 mins ago - Politics & Policy

Celebrities are America's new politicians

Illustration: Annelise Capossela/Axios

Launching gubernatorial bids, making presidential endorsements, founding schools: Celebrities are getting increasingly involved in U.S. public and political life.

Why it matters: As we've reported, politics is no longer just the purview of career politicians, as companies and their CEOs throw their weight around to affect policies. Now, movie stars, famous musicians and professional athletes also are using their influence in politics.

Updated 14 mins ago - Sports

Baseball's minor leaguers get a major win

Illustration: Sarah Grillo/Axios

Starting next season, MLB teams will be required to provide housing for minor league players.

Why it matters: "This is a historic victory," Harry Marino, director of the nonprofit Advocates for Minor Leaguers, told ESPN. It's also just the beginning of a fight for improved quality of life.